Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

June 16, 2024

https://www.globenewswire.com/news-release/2024/06/16/2899284/0/en/Nurix-Therapeutics-Presents-Positive-Results-from-Ongoing-Clinical-Trial-of-NX-5948-in-Patients-with-Relapsed-Refractory-Chronic-Lymphocytic-Leukemia-CLL-at-the-European-Hematology.html

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations

Clinical responses in CLL patients were rapid and deepening with longer time on treatment

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.